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EBOLA PANDEMIC
LURAJEAN CRAVENS, RN, BSN
Otterbein University, Westerville, Ohio
Introduction to Ebola
Ebolavirus, or Ebola Virus Disease (EVD), is of
the filovirus family causing hemorrhagic fever first
discovered in the African country of Zaire in 1976
(Turner, 2014; Hampton, 2014) and has gained
global concern and attention since the recent
epidemic outbreak in West Africa.
There are five known species of Ebola: Zaire,
Sudan, Ivory Coast, Bundibugyo and Reston, based
on the region of origination. The Zaire species has
been identified as the strain responsible for the
current outbreak in West Africa, and has spread to
Liberia, Sierra Leone, Nigeria and Senegal (Centers
for Disease Control and Prevention,2014; Gostin,
Lucey & Phelan, 2014).
The African fruit bat is most likely the carrier
,or vector, for the virus. Human infection results
from direct contact and handling of the infected
bushmeat of bats, primates, antelopes, rats and
other wild animals . Transmission of the virus
between humans occurs only through close
contact with bodily fluids (blood, saliva, sweat,
urine, vomit, breast milk, feces, and semen) of an
infected individual (CDC, 2014; Gostin et al.,
2014).
The mortality rate for contracting the virus
may be up 90%, with the recent virus outbreak
averaging 55-60%(Hampton, T., 2014; CDC, 2014).
There is currently no known cure or vaccine.

Signs & Symptoms
Signs and symptoms of an Ebolavirus infection may include respiratory
infection with pharyngitis and nonproductive cough, flu-like symptoms, fever
greater than 101.5°F, severe headache, muscle pain/ myalgia, body aches,
weakness/malaise, abdominal pain, nausea, vomiting, diarrhea, diffuse
erythematous nonpuritic maculopapular rash(Bray et al, 2014), dermatitis,
kidney and liver dysfunction(CDC, 2014; Turner, 2014). Hemorrhage may
develop with petechiae, bruising, bleeding from mucous membranes, and
internal bleeding; eventually progressing to multi-organ system failure and
septic shock (CDC, 2014).
Lab findings include leukopenia as lymphopenia later followed by elevated
neutrophil count with left shift; thrombocytopenia with platelet counts between
50,000 and 100,000; elevated AST and ALT, elevated PT/PTT consistent with
disseminated intravascular coagulation; and proteinuria (Bray et al, 2014).
Symptoms may begin to develop 2-21 days from exposure to the virus,
with average onset of 8-10 days. Between days 7-9 symptoms may include
headache, fatigue, fever, and muscle soreness. Day 10- sudden high fever and
vomiting blood. Day 11- Bruising, brain damage, bleeding from nose, mouth,
eyes and anus. Day 12- Loss of consciousness, seizures, massive internal
bleeding and death (CDC, 2014).
Infected individuals typically improve 6 days after the onset of
symptoms(Bray et al, 2014). Antigen-antibody complexes formed during
recovery may cause muscle and body aches. More severe, fatal cases will have
more severe signs and symptoms initially and may quickly progress to
multiorgan failure and septic shock, with death occurring between 6-16 days
(Bray et al., 2014).

Nursing Care Implications
There is no known cure or definitive vaccination. Currently the best treatment is supportive
care in maintaining hemodynamic stability, intravenous treatment for fluid and electrolyte
imbalances, respiratory support, blood product replacement for signs of hemorrhage, correcting
coagulopathy and administering antibiotics for infection (Turner, 2014).
Healthcare workers and hospital personnel in direct contact with an infected patient MUST
follow strict protocol to prevent personal exposure and further spread of infection. Universal
precautions should be followed diligently, wearing personal protective equipment (PPE), handling
blood or body fluids with extreme caution for potential exposure. The virus can survive on dry
surfaces such as door knobs and counters for up to several hours , in semen for up to 3 months,
and other body fluids anywhere from 1 week to 30 days(CDC, 2014; Bray et al. 2014). Hospital
grade disinfectants such as bleach are effective for killing the virus from surfaces(CDC, 2014).
Strict isolation with “fever surveillance”(Hampton, 2014) of suspected or lab confirmed
infected patients must be enforced. Hospitals and all healthcare personnel need education on
correct application and removal of personal protective equipment (donning and doffing). It is
important to be familiar with institutional regulations on infectious disease, and the plan of
emergency action in case of a pandemic. There should be strict screening protocols of patients
through hospital ERs with possible symptoms or virus exposure.

Conclusion
The current Ebola outbreak has been declared an
international public health emergency( WHO,2014). The CDC
reports the risk of an Ebola outbreak in the U.S. is low,
recommending limited travel to West African countries.
However, currently there is no ban on travel (Gostin et. al,
2014).
With no known definitive cure or vaccination to prevent
the Ebola virus, strict adherence to preventing the spread must
be continued. Hospitals must maintain strict screening protocols
of all patients who are at risk for exposure.
International efforts to prevent the spread of the virus
have been implemented in major US and West African airports
through entry and exit screening of travelers for infectious signs
and symptoms (CDC, 2014).
The CDC states the rapid identification of Ebola infection is
key to preventing the spread of the virus. “Contact tracing” is
currently a method used by CDC teams to track down infected
persons and is described in the following chart from the CDC
website (2014).
.

Pathophysiology of Ebolavirus
Prevention and Education!

2014 Outbreak
Currently there have been 4 lab-confirmed
Ebolavirus cases in the United States: two imported
cases, including 1 death, and 2 healthcare acquired
cases (CDC, 2014).
The first U.S. case was a patient who had
recently traveled from Liberia to Dallas, TX.,
developing symptoms four days after his arrival.
Lab confirmation was received on October 30th, this
patient died one week later. The following two
cases were healthcare workers who provided direct
care for this patient and tested positive for Ebola
on October 10th and October 15th, respectively
(CDC, 2014). Both have fully recovered and have
been released from isolation (CDC, 2014). The
most recent case is a healthcare worker in New
York who had returned from Liberia and tested
positive on Oct. 23th and remains under isolation
precautions (CDC, 2014).
The 2014 Ebola outbreak is the largest
outbreak in history. As of Nov 7, the total number
of cases was 13,241; total lab-confirmed cases
8,142; and total death count of 4,950 (CDC, 2014).

Ebolavirus is a single stranded RNA virus that enters the body
through mucous membranes, breaks in the skin or intravenously and
attacks many cells of the body including monocytes, phagocytes,
macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes,
adrenal cortical cells and epithelial cells. (Yen et al., 2011, CDC 2014).
The virus migrates from the initial infection site and infects
macrophages and dendritic cells where viral replication occurs, causing
cellular apoptosis and leakage of viral particles into the extracellular fluid.
The replicated virus travels to regional lymph nodes for continued viral
replication, and subsequently to dendritic cells and macrophages in the
liver, spleen, thymus and adrenal glands(Bray, Hirsch & Mitty, 2014).The
virus continues to spread systemically as inflammatory interferon is
suppressed, infecting hepatocytes, adrenal cortical cells, fibroblasts etc.
causing significant tissue necrosis.
The release of cytokines, chemokines, and other inflammatory
mediators such as tumor necrosis factor, interleukins, and nitric oxide
result in a systemic inflammatory response(Bray et al, 2014). Clinical
manifestations of Ebola infection result from the body’s response to the
infection rather than toxicity caused by the virus(Bray et al, 2014).
Infected macrophages with additional stimulation by inflammatory
cytokines releases tissue factor and initiates the coagulation pathway
causing impaired coagulopathy. In addition to hepatic injury, coagulation
dysfunction may ultimately lead to hemorrhage (Bray et al, 2014).
The body’s adaptive immune system begins to fail as a result of
impaired dendritic cellular function and lymphocyte apoptosis (Bray et al.,
2014). This attack on adaptive immunity is how the Ebolavirus can cause
such severe illness and fatality(Bray et al., 2014). Dendritic cells are a
major site for viral replication, preventing maturation of the cells and their
ability to present antigens to lymphocytes. There is also massive apoptosis
of lymphocytes induced by inflammatory mediators and lack of dendritic
signals (Bray et al, 2014).

Public education is paramount in preventing the spread of the virus. Education
would include proper hand washing techniques and hygiene, what symptoms to monitor
for, what to do if suspect exposure or infection, the severity/fatality risk of Ebola virus,
risk factors for transmission, and preventative measures.
.
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Additional Sources

Recovered Ebola patients develop antibodies that may last up to 10 years.
Convalescent therapy of whole blood or plasma transfusions from these
individuals has shown promise for recovery(WHO,2014) of infected individuals.
The WHO has approved implementation of experimental therapies to treat
Ebola individuals (Hampton, 2014) with projected availability by early 2015. There
are several potential vaccines currently undergoing approval for clinical trials. The
CAd3-ZEBOV vaccine developed by GlaxoSMithKline uses chimpanzee-derived
adenovirus vector with an Ebola virus gene inserted(WHO,2014). The rVSV-ZEBOV
vaccine developed in Canada is an attenuated vesicular stomatitis virus found in
livestock with Ebola gene replacement(WHO, 2014). Additional potential
treatments include an SiRNA compund (TKM-Ebola), and AVI-7537m, an antisense
drug (Mullin, 2014; Jarvis, 2014). A recent media release from Japan announced a
potential treatment Avigan, a polymerase inhibitor, is currently awaiting approval
for treatment. The antibody compound Zmapp has already been used for
treatment with both successful and unsuccessful outcomes.

Obama administration is working with specialists
on setting healthcare policy to support potential
experimental treatment therapies for clinical trials
(Hampton, 2014). A major influence on the deployment of
treatment relies highly on international funding. This
certainly would be a major issue in providing potential
treatments for thousands of Ebola infected people. See
additional information regarding international funding for
Ebola treatment in Africa:
http://www.who.int/tdr/news/2014/ebola-treatmenttrials/en/.
Ethical considerations exist concerning using
experimental drugs. There will be limited supplies, many of
which are still awaiting approval for clinical trials (Gostin et al.,
2014). Ethical questions remain as to who would have priority
for treatment, and how and who would make these decisions.
There can be serious, even fatal risks with experimental
therapies and prospective recipients would need to be
educated and understand these risks.
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